Latest SPAC Liquidations: TB SA Acquisition Corp., and Independence Holdings Corp.
TB SA Acquisition Corp. (TBSA) to Liquidate on March 13
TB SA Acquisition Corp. (Nasdaq: TBSA) today announced that as of the close of business on March 13, 2023, the Company’s publicly held Class A ordinary shares will be deemed cancelled and will represent only the right to receive their pro-rata share in the Company’s trust.
The per-share redemption price for the Public Shares will be approximately $10.17.
READIndependence Holdings Corp. (ACQR) to Liquidate on March 10
Independence Holdings Corp. (Nasdaq: ACQR) today announced that it will redeem all of its outstanding Class A ordinary shares, effective as of the close of business on March 10, 2023.
The per-share redemption price for the public shares will be approximately $10.20.
READ
Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....
Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....
1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...
D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...
Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...